Bariatric surgery proves superior to medical and lifestyle management in long-term glycemic control and diabetes remission for T2DM patients, highlighting its viability as a treatment option.
Sino Biological announces services partnership with Rapid Novor
Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, which provides biological research reagents and related technical contract research